26 August 2020 – MPA Webinar Series

Event #1 – Wed 26th August from 7pm to 830pm Topics: Dermatology and Melanoma Surgery Please register via the Eventbrite link: https://www.eventbrite.com.au/e/dermatology-and-melanoma-surgery-a-discussion-with-our-specialists-registration-116189932215?aff=ebdssbeac >> DOWNLOAD PDF for full details

Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website http://australasianmelanoma.org/

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Cancer in the News

Feature Articles

Tesco shoppers ‘appalled’ after summer product announcement

Supermarket giant Tesco has left some shoppers ‘shocked’ with its latest offer.


Posted in Melanoma News, Patients, Latest News

BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients

Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.


Posted in Melanoma News, Health Professionals, Of Interest

Screening and Identification of Key Biomarkers in Melanoma

Malignant melanoma is uncommon worldwide, accounting for only ?1% of all malignant tumors.


Posted in Melanoma News, Health Professionals, Of Interest

Vidutolimod/Nivolumab Under Evaluation in PD-1-Refractory Advanced Melanoma

The safety and efficacy of the combination of vidutolimod (CMP-001) and nivolumab (Opdivo) is currently under investigation in patients with PD-1–refractory advanced melanoma, as part of the ongoing phase 2 CMP-001-010 trial (NCT04698187).1


Posted in Melanoma News, Health Professionals, Of Interest